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ABSTRACT  
BACKGROUND 
The cost-effectiveness of population-based panel-testing for high and moderate penetrance 
ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We evaluate cost-
effectiveness of population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
mutation testing compared to clinical-criteria/family history (FH) testing in unselected 
general population women. 
METHODS 
A decision-analytic model compared lifetime costs and effects of Criteria/FH-based 
BRCA1/BRCA2 testing is compared with BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
testing in those fulfilling Clinical-criteria/strong FH of cancer (≥10% BRCA1/BRCA2 
probability), and all women ≥30 years. Analyses are presented for UK and USA populations. 
Identified carriers undergo risk-reducing salpingo-oophorectomy. BRCA1/BRCA2/PALB2 
carriers can opt for MRI/mammography, chemoprevention or risk-reducing mastectomy. 
One-way and probabilistic sensitivity analysis (PSA) enabled model uncertainty evaluation. 
Outcomes include OC, BC, and additional heart disease deaths. Quality-adjusted life-years 
(QALYs), OC incidence, BC incidence, and incremental cost-effectiveness ratio (ICER) were 
calculated. . The time horizon is lifetime and perspective is payer  
RESULTS 
Compared to Clinical-criteria/FH-based BRCA1/BRCA2 testing, Clinical-criteria/FH-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is cost-effective: 
ICER=£7629.65/QALY or $49,282.19/QALY (0.04 days life-expectancy gained). 
Population-based testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is 
the most cost-effective strategy compared to current policy: ICER=£21,599.96/QALY or 
$54,769.78/QALY (9.34 or 7.57days life-expectancy gained). At £30,000/QALY and 
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$100,000/QALY willingness-to-pay thresholds population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 panel-testing is the preferred strategy in 
83.7% and 92.7% PSA simulations; and Criteria/FH-based panel testing is preferred in 16.2% 
and 5.8% simulations respectively.   Population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% BC and 
3.2%/4.88% OC in UK/USA women: 657/655 OC-cases and 2420/2386 BC cases prevented 
per million. 
CONCLUSIONS 
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-
effective than any Clinicalcriteria/FH-based strategy. Clinicalcriteria/FH-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-effective than 
BRCA1/BRCA2 testing alone. 
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INTRODUCTION 
Our existing healthcare structure is directed predominantly towards treatment rather than 
illness prevention. Advances in genomic medicine are being used to guide novel cancer 
treatment strategies. However, it also offers the opportunity to deliver a new population-
based predictive, preventive, personalized, and participatory (P4) medicine strategy for 
cancer prevention. Traditionally ovarian cancer (OC)/breast cancer (BC) prevention has been 
targeted at high-risk individuals like BRCA1/BRCA2 mutation carriers. At-risk mutation 
carriers can opt for: risk-reducing salpingo-oophorectomy (RRSO) to reduce their OC-risk 
(1,2), MRI/mammography screening, risk-reducing mastectomy (RRM) (3), or 
chemoprevention with selective estrogen-receptor-modulators (SERM) to reduce their BC-
risk (4), as well as pre-implantation genetic-diagnosis (PGD) (5). Identification of mutation 
carriers (e.g. BRCA1/BRCA2) at high-risk of OC/BC has involved genetic-testing affected 
individuals or those from high-risk families in specialised genetics clinics. Clinical-
criteria/family-history (FH) are surrogates for BRCA probability with testing offered above a 
certain threshold. However, clinical-criteria/FH-based testing is only moderately effective at 
identifying mutations and has poor ability to rule out the absence of one (6). We (7) and 
others (8,9) have shown that this approach misses >50% mutation carriers. Given the 
effective options available for OC and BC risk management/prevention, this raises serious 
questions about the adequacy of a Clinical-criteria/FH-based approach. Additionally lately, 
newer intermediate/moderate risk OC-genes RAD51C,(10) RAD51D(11) and BRIP1(12) 
(OC-risks ~5-9%), have been identified and their penetrance estimates validated (13,14). 
Furthermore, our recent modelling work strongly suggests that RRSO would be cost-effective 
at ≥4-5% OC-risk (15,16). This enables clinical-utility and supports implementation of 
clinical testing for these gene mutations. Amongst the newer moderate-risk BC-genes, 
PALB2 is the one that confers non-syndromic quasi-Mendelian susceptibility to BC (BC-
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risk=44%) (17) for which equivalent interventions (RRM/breast-MRI) are now offered to 
mutation carriers. ATM, CHEK-2 have lower moderate risks (RR~1.5-2) which don’t justify 
RRM. Testing for these though commercially available, is not currently routinely undertaken 
in clinical practice (18,19). 
The limitations of Clinical-criteria/FH-based ascertainment can be overcome by 
population-based testing. Next-generation sequencing technologies (20,21) with high-
throughput multiplex panel-testing, falling costs, and advances in computational 
bioinformatics has made population-testing feasible. In a prospective randomised trial we 
showed that compared to FH-based testing, population-based BRCA1/BRCA2 testing in 
Ashkenazi-Jews(AJ) is acceptable, feasible, can be undertaken in a community setting, 
doesn’t harm psychological health/quality-of-life, identifies >50% additional carriers, reduces 
BC-&-OC incidence, and is extremely cost-effective (incremental-cost-effectiveness-ratio 
(ICER)=-£2079/quality-adjusted-life-year (QALY)) (7,22). While, there is good evidence to 
support a change in the clinical paradigm from Clinical-criteria/FH to population-based 
testing in Ashkenazi-Jews (23), a population-based approach has not yet been properly 
evaluated in the non-Jewish general population. A health-economic assessment is crucial for 
evaluating and comparing the efficacy of different health interventions. This helps allocate 
resources across interventions, and set policy to improve population health. Here we use a 
decision-analysis model to compare the costs-&-effects of Clinical-criteria/FH and 
population-testing approaches for the known high and moderate penetrance OC/BC gene 
mutations: BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2.  
 
METHODS 
Ethics approval: This analysis was approved under the ethics approval obtained for the 
Genetic Cancer Prediction through Population Screening (GCaPPS) study, from the Institute 
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of Child Health/ Great Ormond Street Hospital Research Ethics Committee: REC Reference 
number 08/H0713/44.  
Decision Model 
A decision-analytic model (Figure 1) was developed to compare the lifetime costs-&-
effects of genetically testing all non-Jewish women ≥30 years for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations compared with the current practice of clinical-
criteria/FH-based testing (based on ≥10% BRCA1/BRCA2 mutation probability alone) (19). 
We present separate analyses for both UK and USA populations. The standard clinical-
criteria/FH-based testing for BRCA1/BRCA2 mutations is compared in an incremental fashion 
to (Strategy-A): Clinical-criteria/FH-based panel testing for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations and (Strategy-B): Population-
testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations. The model assumes 
all women in the population-screening arm and only those fulfilling clinical/FH-criteria in the 
FH-arm are offered genetic-counselling and genetic-testing. We assume 71% will uptake 
genetic-testing (from GCaPPS study) (7). The cost of pre-test counselling is included (24,25). 
BRCA1/BRCA2 negative women are tested for RAD51C/RAD51D/BRIP1/PALB2 mutations 
(from the same DNA sample). A detailed description of all model assumptions is given in 
Supplementary Table 1. The model incorporates the increased risk of cardiovascular 
mortality (absolute increase=3.03%) reported with pre-menopausal bilateral-oophorectomy in 
women who don’t take hormone replacement therapy (HRT) (26,27). Model outcomes 
included OC, BC and excess deaths from heart disease. As per National Institute of Health 
and Care Excellence(NICE) economic evaluation guidelines, costs and outcomes are 
discounted at 3.5% (28). 
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Probabilities 
We use the most up-to date prevalence estimates for BRCA1/BRCA2 (29) and RAD51C, 
RAD51D (14), BRIP1 (13), and PALB2 (30). The probability of having a positive FH or 
fulfilling clinical criteria for non-AJ genetic testing is obtained from previously unpublished 
unselected control population data from the Australian Breast Cancer Family Registry 
(ABCFR). The different pathway probabilities are specified in Table 1 (explanation in 
Supplementary Table 2). Cancer incidence was estimated by summing the probabilities of 
pathways ending in OC or BC. The possibility of both OC and BC occurring simultaneously 
is rare and presumed close to zero. The potential population impact was calculated by 
translating reduction in BC and OC incidence obtained across the population of non-AJ 
UK/USA women. 
 
Costs 
All costs (Supplementary Table 3) are reported at 2014 prices (31) and derived from a 
healthcare system/payer’s perspective. Costs were converted wherever needed using the 
Hospital and Community Health Service Index (32). As per NICE recommendations future 
healthcare costs not associated with OC/BC or cardiovascular disease were not considered 
(28).  
 
Life-years 
The analysis has a lifetime time-horizon covering lifetime risks as well as long-term 
consequences. Female lifetables from the Office of National Statistics (UK women) and 
SEER (USA women) were used for life expectancy data for women not developing OC/BC 
(33). To simplify the analysis we used average estimates for ages of onset and survival for 
BRCA1/BRCA2 related BC and OC. Details of ages of onset and survival estimates used are 
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in Supplementary Table 4. The average ages for BC/OC were 44.4/59.6 years respectively 
for BRCA1+BRCA2 carriers (34). The median ages of onset of sporadic OC/BC were 68/60 
and 63/62 years in the UK and USA populations respectively (from CRUK/SEER) (35-37). 
OC/BC outcomes were modelled using 10-year survival data.  
 
Quality-adjusted-life-years (QALYs) 
QALYs are recommended by NICE as the most suitable summary measure for economic 
evaluation of health outcomes. It adjusts changes in length-of-life, by potential alterations in 
quality-of-life and thus reflects both mortality and health-related quality-of-life effects (28). 
QALY=(Survival in life-years)x(Utility-weight). Calculating QALYs requires knowledge of 
utility weights for each health state in the model. ‘Utility weight’ is an adjustment for quality-
of-life. It indicates an individual’s preference for specific health state where ‘1’=perfect 
health and ‘0’=death. The utility-scores used are described in Supplementary-Table 5.  
 
Analysis 
Figure 1 illustrates the decision-model. Path probabilities (Supplementary-Figure 1) were 
multiplied to calculate each branch probability. The total costs-and-effects in terms of life-
years and QALYs were estimated by weighting the values for each branch by the branch 
probability. The ICER was estimated by dividing the difference in cost by the difference in 
effect between strategies. ICER=(Cost A–Cost B)/(Effect A–Effect B). This ICER obtained is 
compared with the cost-effectiveness willingness-to-pay (WTP) thresholds of NICE 
<£30000/QALY (38) (UK analysis) and USA $100,000/QALY (39,40) (USA analysis) to 
determine whether or not population screening for all women can be cost effective compared 
with clinical-criteria/FH-based testing. Additional scenario analyses were also undertaken: (a) 
no benefit of reduction in BC-risk; (b) varying genetic-testing costs to define UK and USA 
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cost-thresholds for cost-effectiveness; (c) higher all-cause mortality from premenopausal 
oophorectomy, and (d) lower RRSO/RRM uptake.  
Sensitivity analyses explored uncertainty in results and robustness of the model. In a 
one-way sensitivity analysis, each model parameter is varied individually to evaluate impact 
on results. Probabilities/utility weights were varied according to 95% confidence-
intervals/range, where available, or by +/-10%. Costs were varied by +/-30%. Given, model 
parameters/variables are likely to vary in parallel rather than independently, probabilistic 
sensitivity analysis (PSA) was also undertaken (28,41). It permits variables to be varied 
simultaneously across their distributions and is recommended by NICE (28). The PSA was 
fitted with appropriate distributions recommended in the literature (probabilities=beta; 
costs=gamma; utilities=log-normal) (42). A cost-effectiveness acceptability curve plotted the 
result of 10,000 simulations for all strategies. It depicts the proportion of cost-effective 
simulations for each strategy at the various WTP thresholds. The sum of the (cost-effective) 
proportions for all strategies taken together at any given WTP threshold is always=1. 
 
RESULTS 
The comparison of decision model outcomes of the three different testing strategies for 
undiscounted and discounted lifetime costs, life-years(survival), and QALYs is given for both 
UK and US women in Table 2. Discounting reduces the overall cost difference as well as 
gain in life-years/QALYs. This is because future costs/outcomes are adjusted by discounting 
and cost-savings which are generated through preventing future BC/OC are considered lower 
in value. Our results show that both newer strategies are cost-effective compared to the 
current clinical-criteria/FH-based BRCA1/BRCA2 testing policy. Compared to Clinical-
criteria/FH-based BRCA1/BRCA2 testing, Clinical-criteria/FH-based panel testing for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is highly cost-effective: 
11 
 
ICER=£7,629.65/QALY or $49,282.19/QALY (0.04days life-expectancy gained). A 
population-based panel-testing strategy for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
mutations is the most cost-effective strategy compared to current policy: 
ICER=£21,599.96/QALY (9.34days life-expectancy gained) or $54,769.78/QALY (7.57days 
life-expectancy gained). 
Results of the one-way sensitivity-analysis (Figure 2; Supplementary Figures 2 and 
3) indicate that for Strategies-B and A, model-outcomes are not impacted that much by 
different model parameters (Supplementary Tables 2 and 3), mutation prevalence, surgical 
prevention costs, utility-scores or treatment of OC/BC or cardiovascular disease. Despite 
varying parameters at extremes of their CIs/range, the model remains cost-effective at the 
<£30,000/QALY or $100,000/QALY thresholds. The model is cost-effective at the lower 
limits of RRSO (30%) and RRM (34%). 
PSA results (Figures 3 and 4) show that at £30,000/QALY WTP-threshold 
population-testing for all gene mutations (strategy-B) is the preferred strategy in 83.7% 
simulations and Clinical-criteria/FH-based panel-testing for all gene mutations (strategy-A) is 
preferred only in 16.2% simulations.  Correspondingly, in American women, strategy-B is the 
preferred strategy at $100,000/QALY WTP threshold in 92.7% simulations. A population-
testing strategy is more cost-effective than any clinical-criteria/FH-testing strategy, with 
strategy-B emerging as the most cost-effective. Taken together, this clearly indicates cost-
effectiveness and overall preference for a population testing approach for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations in the general population.  
 Scenario analyses are presented in Table 3. The alternative strategies-A and B still 
remain cost-effective at the UK/USA WTP-thresholds compared to the current clinical 
strategy, even if there is no reduction in BC-risk from RRSO (ICER=£27,632.95/QALY or 
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$72,221.37/QALY) and for lower RRM and RRSO rates. Population-testing remains cost-
effective until the genetic-testing costs rise to £250/test or $772/test.  
 BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% 
BC and 3.2%/4.88% OC in UK/USA women: 657/655 OC cases and 2420/2386 BC cases 
prevented per million. The overall proportion and number of BC/OC cases prevented as well 
as excess cardiovascular deaths from general (non-Jewish) population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is given in Table 4. 
 
DISCUSSION 
Our analysis for the first time addresses the important topical issue of cost-effectiveness of a 
population-based strategy for testing moderate/high-penetrance OC/BC gene mutations in the 
general population. It justifies cost differences for different interventions by providing 
QALY-based health outcomes. This is required to guide policy decisions on healthcare 
resource allocation for disease prevention. Our findings that a population-based genetic 
testing strategy for OC/BC gene mutations outperforms any clinical-criteria or FH-strategy, 
with 84%-93% simulations cost-effective on PSA (£30,000/QALY and $100,000/QALY 
thresholds) are extremely noteworthy. Such a population-based program implemented in 
women >30years could result in 17,505/65,221 fewer OC and 64,493/237,610 fewer BC 
cases in British/American women respectively. This can have a much greater impact on the 
burden of disease than any current treatment strategy. Our data also highlight the need to 
move from BRCA1/BRCA2 testing to panel-testing incorporating additional 
RAD51C/RAD51D/BRIP1/PALB2 mutations within a clinical-criteria/FH-based strategy 
itself. These results have important implications for clinical care and OC/BC prevention. 
They could also be valuable to program evaluators/managers, policy makers, and healthcare 
commissioners.  
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Long and Ganz (43) used our AJ decision-analysis model (22) to evaluate systematic 
BRCA1/BRCA2 testing in the general non-Jewish population and found it not to be cost-
effective (43). However, AJ estimates/parameters should not be used to evaluate general 
population-testing, which may be a reason their analysis gives apparently incorrect/different 
results. For example, they use AJ estimates for prevalence of FH of cancer. However, 
clinical/FH-criteria are far more stringent and prevalence of such individuals is much lower 
in the general compared to the AJ-population. These data were previously unpublished and 
obtained from the ABCFR control population for our analysis. Additionally our current 
model and analysis is different, more comprehensive; uses general non-AJ estimates and 
compares two new panel testing strategies to the current gold-standard of Clinical-
criteria/FH-based BRCA1/BRCA2-testing. 
Our analysis has several advantages. It fulfils various principles listed by NICE for 
economic analyses including preferred type of economic evaluation (28). We use NICE 
guideline and clinical criteria-based current BRCA1/BRCA2 testing policy as the best practice 
comparator. Additionally, QALYs are used to measure health effects, utilities are 
incorporated and costs and outcomes discounted at 3.5%. Model parameters are derived from 
well-established/proven information from the literature and up-to-date data from the 
PROMISE programme, GCaPPS study, and Australian BC registry. The time-horizon is 
sufficient to reveal important differences in costs and outcomes, and costs of pre-test 
counselling plus testing are included. Besides OC/BC outcomes we also included excess 
coronary deaths from premenopausal oophorectomy (26). To avoid over-estimating the 
advantages of population testing, we used conservative costs for OC/BC diagnosis, treatment 
and management of recurrence (44). The extensive sensitivity analysis presented adds rigour 
to the results. Costs of counselling, RRSO, chemoprevention and treatment of 
OC/BC/coronary disease do not influence overall results. Results remain cost-effective even 
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at extremes of BRCA1/BRCA2 prevalence/penetrance estimates. Our analysis also highlights 
the need for better precision around prevalence and penetrance estimates of 
RAD51C/RAD51D/BRIP1/PALB2 mutations as the CIs for these are extremely wide.  This 
requires further research.  
A limitation may be considering only cardiovascular mortality (not morbidity) from 
early oophorectomy. However, we include costs for all excess cardiovascular disease and 
one-way sensitivity-analysis shows these parameters don’t substantially impact results. 
Another limitation may be our exclusion of increased lung/colorectal cancer mortality from 
premenopausal oophorectomy reported in the Nurses Health Study (26). However, this 
finding was not validated/reproduced in the 337,802 women EPIC study (45). Additionally, 
this excess mortality is confounded by smoking/risk related behaviors. The NIH-AARP Diet 
and Health Study found oophorectomy associated increased lung cancer risk was limited to 
smokers (46). Additionally, cardiovascular risk can also be confounded by smoking. Besides 
cohort data show that RRSO is associated with an overall 77% reduction in all-cause 
mortality (47), which will further improve cost-effectiveness. Nevertheless, even if we 
assumed a higher all-cause mortality (1:8), the model remains cost-effective for population-
screening (ICER=£22,820/QALY and $58,561/QALY, 8.7 and 6.9 days life-expectancy 
gained).  
We assume a 71% uptake of genetic-testing. However, the true uptake in non-AJ 
women needs to be addressed in future studies. Acceptability/uptake of population-based 
panel-testing is being assessed by us in the PROMISE pilot study (48). Premature surgical 
menopause is associated with worse sexual-functioning and vasomotor symptoms without 
decreasing generic quality-of-life (49-52). While HRT ameliorates detrimental consequences 
of premature menopause, symptom levels are still higher than those retaining their ovaries  
(51).  This can be offset by reduced cancer worry, decrease in perceived risk, and high 
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satisfaction rates found with surgical prevention (49,50). These issues along with a small (~3-
4%) complication rate(53) should be part of informed consent and RRSO decision making 
process. While we assume 80% HRT compliance, the true compliance in a larger population-
based cohort remains to be determined. It is important for these women to have long-term 
follow-up and monitoring of bone/cardiovascular health and receive psychosexual support.  
The utility of concomitant hysterectomy along-with RRSO has been debated. 
Proponents of hysterectomy cite the benefits of estrogen-alone HRT (no increased BC/heart 
disease risk) (54) and avoiding cervical smears. The impact and context of HRT in women 
undergoing premenopausal oophorectomy is completely different to that of older post-
menopausal WHI women. Short-term HRT in BRCA1/BRCA2 carriers undergoing 
premenopausal oophorectomy doesn’t increase BC-risk (55). HRT is protective for heart 
disease in premenopausal oophorectomized women (26,27), will be stopped at 50years (age 
of menopause), and does not increase cardiovascular risk in the post-menopausal post-
intervention phase (54). Hysterectomy has higher morbidity, complication rates, costs, longer 
operating time and hospital stay/recovery. Hysterectomy is not routinely offered as an 
alternative to progesterone HRT or to Tamoxifen in BC. With Tamoxifen (the absolute 
increase in endometrial-cancer (EC) risk is small (56),  and ACOG/RCOG guidelines only 
recommend urgent investigation of unscheduled/abnormal bleeding.(57,58). Recent reports 
suggest increased ‘serous’-EC risk in BRCA1 (59,60). However, serous-EC comprises ~7% 
of overall-EC (61), number of cases were small, CIs wide, absolute EC-risk (~3%) remains 
small, and overall EC-risk is not statistically significantly increased (59,60).. A recent cost-
effectiveness analysis had limitations. It only included women undergoing mastectomy and 
lacked a disutility for hysterectomy (62). Further corroborating data are needed and the issue 
of hysterectomy may then need revisiting. The risk-benefit profile doesn’t currently justify 
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routine hysterectomy at RRSO for OC-risk reduction(63), and most centres don’t practice 
this. 
In line with a number of analyses in high (2,64,65) and low-risk (66) women our 
base-model incorporates a reduction in BC-risk with pre-menopausal oophorectomy. 
Conversely, a recent Dutch article (67)  found no such effect. However, the follow-up was 
short (3.2years)(67), and longer follow-up data are awaited.. Nevertheless, our scenario 
analysis reconfirms cost-effectiveness of strategy-A and strategy-B even if pre-menopausal 
oophorectomy doesn’t decrease BC-risk. RAD51C/RAD51D/PALB2 have been considered 
as single cancer genes only. However, should future evidence show both increased OC and 
BC, it would increase cost-effectiveness of population-testing.  
Our model incorporates the impact of breast screening already prevalent and RRM. 
While RRM is weighted for a 21% complication rate, any reduction in QALYs is not 
included. Although RRM is linked with a negative impact on body-image and sexual 
pleasure, no detrimental impact on sexual-activity, habit, discomfort (68), anxiety, depression 
or quality-of-life was reported (68-70). Besides, adverse consequences may be balanced by 
decreased anxiety, increased social activity(68) and high cosmetic satisfaction rates (69,71-
73). 
Genomic, clinical and biological information is being combined through precision-
medicine initiatives like the 100,000-Genomes (74) and Moonshot (75) projects to optimise 
clinical decisions for personalized treatment. . Importantly these advances also offer the 
opportunity for personalised cancer prevention. This can have a much bigger impact on 
reducing burden of disease but requires a shift in focus to the unaffected population. We 
show for the first time that introduction of systematic genetic-testing in the general 
population for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is a cost-
effective strategy that can reduce OC and BC incidence and save lives. This form of panel-
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testing can potentially be expanded to include other gene mutations with established ‘clinical-
utility’ for cancer prevention. Our findings pave the way for research studies in carriers 
ascertained through population means to evaluate and understand impact on psychological-
health, quality-of-life, long-term health behaviour and reconfirm uptake rates of 
screening/surgical prevention strategies. Additionally big services re-design and 
implementation issues affecting major system change/intervention outcomes (76,77) need 
addressing before introducing such a programme. Furthermore, a robust system/platform for 
monitoring and re-classifying (as required) variants of uncertain-significance (VUS) detected 
needs establishing. Other issues that need addressing include raising public/health 
professional awareness, education, delivery logistics, quality-control, call-recall mechanisms 
and fail-safe checks/processes for quality assurance. All these have additional costs. Further 
development/expansion of co-ordinated/integrated clinical pathways between primary and 
tertiary care involving GPs, geneticists, gynaecologists, breast teams are needed for managing 
high-risk women. Given extreme cost-effectiveness  (78), of AJ-population BRCA-testing, 
panel-testing incorporating additional OC/BC genes would be cost-effective too and should 
be considered. The global cancer burden is expected to rise by 75%(79) and the number of 
BC/OC cases by 24%/27% in the UK and 34%/39% in the USA respectively by 2035 (80). 
Cancer prevention is key to achieve long-term transformational change and cost-efficiencies 
in our health-system. It is important we seize the opportunity offered to facilitate 
implementation of genomics for cancer prevention in healthcare. 
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Tables 
 
Table-1: Probabilities of different pathways in the model* 
 
Probability  Value (95%CI) [Range] Description  Source  
P1 0.00677 (0.0059-0.0077) 
BRCA1/BRCA2 mutation 
prevalence in a general population  Jervis 2015(29) 
P2 0.47 (0.34-0.56) Probability that carrier will undergo RRM Evans 2009(81) 
P3 0.96 [0.8-0.96] Reduction in risk of ovarian cancer from RRSO 
Finch 2006,(1) 
Rebbeck 2009(2) 
P4 0.202 [0.17-0.28] 
Probability that BRCA1/BRCA2 
carrier without RRSO will get 
ovarian cancer 
Antoniou 2008 
BOADICEA,(82) 
Chen 2007(83) 
P5 
0.02 (0.001, 0.06) Probability that a non-carrier will get ovarian cancer CRUK 2015(84) 
0.0128 (0.0126- 0.0130) 
Probability that a non-carrier will 
get ovarian cancer – USA 
estimate 
SEER(85) 
P6 0.0098 (0.0047, 0.0179) 
Probability of having a positive 
FH  fulfilling non-AJ genetic 
testing criteria 
ABCFR data 
P7 0.1  
BRCA1/BRCA2 prevalence in 
those fulfilling clinical criteria or 
FH positive  individuals 
Current testing 
guideline 
P8  0.0056 (0.0049, 0.0066) 
BRCA1/2 Mutation prevalence in 
FH negative individuals 
Jervis 2015,(29) 
ABCFR data 
P9 0.911 (0.62-0.98) 
Reduction in breast cancer  risk 
from RRM without RRSO in 
BRCA1/2 carriers 
Rebbeck 2004(3) 
P10 0.644 [0.42-0.67] 
Probability that BRCA1/2 carrier 
without RRM will get breast 
cancer 
Antoniou 2008 
BOADICEA,(82) 
Chen 2007(83) 
P11 
0.129 [0.11-0.14] 
Probability that a non-BRCA1/2 
carrier will get breast cancer with 
screening 
CRUK 2015(84) 
0.124 (0.1236- 0.1249) 
Probability that a non-BRCA1/2 
carrier will get breast cancer with 
screening – USA estimate 
SEER(85) 
P12 0.55 (0.30-0.75) Probability that mutation carrier will follow-up with RRSO 
Manchanda 
2012(86) 
P13 0.49 (0.37-0.65) HR for breast cancer from RRSO alone in BRCA1/BRCA2 carrier Rebbeck 2009(2) 
P14 0.95 (0.78-0.99) 
Reduction in risk of breast cancer 
from RRM with RRSO in 
BRCA1/BRCA2 carriers 
Rebbeck 2004(3) 
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P15 0.002 (0.0003, 0.0036) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in unselected 
general population controls 
Song 2015,(14) 
Ramus 2015(13) 
P16 0.089 (0.05, 0.17) 
Probability that RAD51C, 
RAD51D, BRIP1 carrier without 
RRSO will get ovarian cancer  
Loveday 
2012,(10) 
Loveday 
2011,(11) Ramus 
2015(13) 
P17 0.94 (0.83-0.98) 
Reduction in ovarian cancer risk 
from RRSO in RAD51C, 
RAD51D, BRIP1 
Parker 2013(26) 
P18 0.62 (0.53-0.74) 
HR of breast cancer from RRSO 
alone in RAD51C, RAD51D, 
BRIP1 
Parker 2009(87) 
P19 0.0122 (0.0074, 0.017) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
positive (BRCA1/2 negative) 
individuals 
Song 2015,(14) 
Ramus 2015(13) 
P20 0.00186 (0.00023, 0.0034) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
negative individuals 
Song 2015,(14) 
Ramus 2015(13) 
and ABCFR data 
P21 0.0303 (0.011,0.043) Risk of mortality from CHD after RRSO Parker 2013(26) 
P22 0.8 (0.76,0.83) Compliance with HRT Read 2010(88) 
P23 0.71 (0·60–0·83) HR of breast cancer risk from chemoprevention Cuzick 2015(89) 
P24 0.163 (0.136, 0.19) Uptake of breast cancer chemoprevention Smith 2016(90) 
P25 0.00125 (0.0008, 0.0017) 
PALB2 Mutation prevalence in 
unselected general population 
controls 
Slavin 2017(30) 
P26 0.44 (0.34, 0.55) 
Probability that PALB2 carrier 
without RRM will get breast 
cancer 
Antoniou 
2014(17) 
P27 0.0089 (0.0079, 0.0099) 
PALB2 Mutation prevalence in 
FH positive (BRCA1/2 negative) 
individuals 
Buys 2017(91) 
P28 0.0012 (0.00073, 0.0016) 
PALB2 Mutation prevalence in 
FH negative individuals 
ABFCR data, 
Buys 2017(91), 
Slavin 2017(30) 
P29 0.0072 (0.0068, 0.0076) Excess risk of CHD after RRSO Parker 2013(26) 
*95%CI- 95% confidence interval, ABCFR- Australian Breast Cancer Family Registry, 
CHD- Coronary heart disease, CRUK- Cancer Research UK, FH- family history, HRT- 
hormone replacement therapy , RRSO- risk reducing salpingo-oophorectomy, RRM: Risk 
reducing Mastectomy. A detailed explanation of the various probabilities is given in 
Supplementary Table 1 
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Table 2.  Model Outcomes for the different genetic testing strategies: undiscounted and discounted Costs, Quality Adjusted Life Years 
(QALYs) and Incremental Cost-effectiveness Ratio (ICER) per QALY 
  Undiscounted Discounted  
 
Strategy 
Cost 
(UK=£, 
USA=$) 
Life 
years QALYs  
Cost 
(UK=£, 
USA=$) Life years QALYs  
ICER in 
£/QALY or 
$/QALY  
U
K
 E
st
im
at
es
 
*Standard FH based testing for 
BRCA1/BRCA2 mutations £4423.25 52.2850 52.0822 £1586.11 23.7621 23.6909 -* 
FH based testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations £4423.23 52.2851 52.0823 £1586.38 23.7621 23.6909 £7629.65 
Population testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations £4586.86 52.3107 52.1116 £1779.73 23.7693 23.6999 £21599.96 
U
SA
 E
st
im
at
es
 *Standard FH based testing for BRCA1/BRCA2 mutations $19252.85 52.5063 52.3139 $6795.73 23.8127 23.7478 -* 
FH based testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations $19253.14 52.5064 52.3140 $6797.35 23.8128 23.7479 $49282.19 
Population testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations $19515.76 52.5271 52.3386 $7207.90 23.8185 23.7553 $54769.78 
 
*Reference strategy.  FH- family history, QALY- Quality Adjusted Life Years, ICER- Incremental Cost-effectiveness Ratio 
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Table-3: Scenario Analysis: UK and USA model outcomes for different scenarios  
SCENARIO ANALYSIS 
  UK Estimates USA Estimates 
  Strategy A Strategy B Strategy A Strategy B 
 
SCENARIOS 
ICER/QALY 
(£) 
LE 
gained 
(days) 
ICER/QALY 
(£) 
LE 
gained 
(days) 
ICER/QALY 
($) 
LE 
gained 
(days) 
ICER/QALY 
($) 
LE 
gained 
(days) 
 No reduction in BC risk from 
RRSO (p13=1, p18=1) 9,540.39 0.04  27,632.95 7.8 57,693.62 0.04 72,221.37 6.5 
 Lowest cost-effective RRM 
(p2) uptake rate: p2=19% 
(UK), p2= 8% (USA) 16,564.53 0.03 29,985.08 7.3 151,005.84 0.024 99,851.74 5.6 
 Lowest cost-effective RRSO 
(p12) uptake rate: p12= 22% 
(UK), p2= 13% (USA) 7,298.79 0.03 29,970.42 6.4 71,788.24 0.024 99,969.56 4.1 
 Lower RRM (p2) plus RRSO 
(p12) cost-effective rates: UK 
(p2 = 36% & p12 = 36%); (p2 
= 32% & p12 = 32%) 9,965.86 0.03 29,984.88 6.8 93,684.20 0.03 99,653.60 4.8 
 Genetic Testing cost £250 or 
$772 (thresholds at which 
population testing remains 
cost-effective) 7,629.65 0.04 29,896.23   9.4 49,282.19 0.04 99,947.44 7.6 
 
Strategy-A: FH based testing for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutations 
Strategy-B: Population testing for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutations   
QALY- Quality Adjusted Life Years, ICER- Incremental Cost-effectiveness Ratio; LE – Life expectancy; RRM – Risk reducing mastectomy; 
RRSO – Risk reducing salpingo-oophorectomy; BC- breast cancer  
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Table 4. Overall impact of General (non-Jewish) Population Testing for 
BRCA1/BRCA2/ RAD51C/RAD51D/BRIP1/PALB2 mutations in women >30 years* 
Population Testing for BRCA1/BRCA2/ 
RAD51C/RAD51D/BRIP1/PALB2 mutations UK women USA women 
Proportion of BC cases prevented 1.86% 1.91% 
Number of BC cases prevented per million women 2420 2386 
Number of BC cases prevented in the total population 
(26.65M UK and 99.6M USA women) 64493 237610 
Number of deaths from BC prevented per million 
women 523 367 
Number of deaths from BC prevented in the total 
female population 13930 36591 
Proportion of OC cases prevented 3.20% 4.88% 
Number of OC cases prevented per million women 657 655 
Number of OC cases prevented in the total population 
(26.65M UK and 99.6M USA women) 17505 65221 
Number of OC deaths prevented per million  461 460 
Number of OC deaths prevented in the total female 
population 12298 45857 
Number of excess deaths from heart disease per 
million women 25 25 
Number of excess deaths from heart disease in the 
total population 
(26.65M UK and 99.6M USA women) 
666 2490 
 
*The estimated female population (non-Jewish) >30years ~26.65M in the UK(92,93) and 
99.6M in USA.(94,95). BC – breast cancer, OC – ovarian cancer, M – million 
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Figure Legends 
 
Figure 1. Decision Analysis Model.  The Right half of the model reflects a population-based 
approach to testing from BRCA1, BRCA2, RAD51C, RAD51D,BRIP1 and PALB2 mutations. 
The left half of the model reflects a clinical criteria/ family history based testing approach for 
the same. Each decision point in the model is called a ‘node’ and each path extending from a 
node is called a decision ‘branch’. Each branch represents a mutually exclusive course or 
outcome. Each decision is given a probability highlighted along the decision branch. The 
probabilities used in the model are explained in Table-1 and Supplementary Table-S1. Values 
for each outcome are calculated. Cancer incidence was estimated by summing the 
probabilities of pathways ending in ovarian or breast cancer. Final outcomes of each path 
include development of breast cancer (BC), ovarian cancer (OC), no breast/ovarian cancer 
(no OC or BC) and excess deaths from coronary heart disease (CHD).   
Abbreviations: BC- Breast Cancer, CHD- Coronary heart disease; OC-Ovarian Cancer; No 
OC or BC- No Ovarian Cancer or Breast Cancer developed., RRSO –Risk reducing salpingo-
oophorectomy; RRM – Risk reducing mastectomy; BRCA- BRCA1 & BRCA2; RAD+ - 
RAD51C, RAD51D & BRIP1 
 
 Figure 2. One way Sensitivity Analysis: Population screening for BRCA1, BRCA2, 
RAD51C, RAD51D, BRIP1 and PALB2 mutations in UK & USA women.  One-way 
sensitivity analysis for all probabilities, costs and utilities in terms of ICER of UK and USA 
Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2 
mutations, compared to a Clinical-criteria / FH-based approach for BRCA1 and BRCA2 
testing. Y-axis: Incremental cost-effectiveness ratio (ICER): Cost (£s or $s) per quality 
adjusted life year (QALY) (discounted). X-axis: Probability, cost and utility parameters in the 
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model. The model is run at both lower and upper values/limits of the 95% confidence interval 
or range of all probability parameters described in Table-1/methods; and both lower and 
upper values/limits of the cost and utility-score parameters given in Table 2. Costs are varied 
by +/- 30%. ‘Maximum value’ represents outcomes for upper limit and ‘minimum value’ 
represents outcomes for lower limit of the parameter.  
 
Figure 3. Probabilistic Sensitivity Analysis: UK women.  Probabilistic sensitivity analysis 
in which all model parameters/ variables are varied simultaneously across their distributions 
to further explore model uncertainty.  X-axis: Incremental cost-effectiveness ratio (ICER) in 
terms of Cost (£s))/QALY; Y-axis: Proportion of simulations. The results of 10,000 
simulations were plotted on a cost-effectiveness acceptability curve showing the proportion 
of simulations (Y-axis) that indicated that the intervention was cost-effective at different 
willingness to pay thresholds (X-axis). The dotted line in Fig 4, marks the proportion of 
simulations found to be cost-effective at the £30,000 UK threshold used by NICE. Bold line 
Curve – Standard Clinical-criteria/ Family-history based testing for BRCA1/BRCA2 
mutations. 
Curve A- Clinical-criteria/ Family-history based testing for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations  
Curve B - Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and 
PALB2 mutations  
At any given point on the WTP-threshold scale, the sum of proportion of cost-effective 
simulations for all three strategies is always =1. 
At the £30,000/QALY willingness to pay threshold, 16.2% simulations are cost-effective for 
Clinical-criteria/ Family-history based testing for all gene mutations (Curve A) and 83.7% 
simulations are cost-effective for population-testing for all gene mutations (Curve B).  
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A population-testing strategy is more cost-effective than any Clinical-criteria/FH-testing 
strategy 
 
Figure 4. Probabilistic Sensitivity Analysis: USA women.  Probabilistic sensitivity 
analysis in which all model parameters/ variables are varied simultaneously across their 
distributions to further explore model uncertainty.  X-axis: Incremental cost-effectiveness 
ratio (ICER) in terms of Cost ($s))/QALY; Y-axis: Proportion of simulations. The results of 
10,000 simulations were plotted on a cost-effectiveness acceptability curve showing the 
proportion of simulations (Y-axis) that indicated that the intervention was cost-effective at 
different willingness to pay thresholds (X-axis). The dotted line marks the proportion of 
simulations found to be cost-effective at the $100,000 USA willingness to pay (WTP) 
threshold. 
Curve with Bold Line – Standard Clinical-criteria/ Family-history based testing for 
BRCA1/BRCA2 mutations 
Curve A- Clinical-criteria/ Family-history based testing for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations  
Curve B - Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and 
PALB2 mutations  
At any given point on the WTP-threshold scale, the sum of proportion of cost-effective 
simulations for all three strategies is always =1. 
At the $100,000/QALY willingness to pay threshold, 5.8% simulations are cost-effective for 
Clinical-criteria/ Family-history based testing for all gene mutations (Curve A) and 92.7% 
simulations are cost-effective for population-testing for all gene mutations (Curve B).  
A population-testing strategy is more cost-effective than any Criteria/FH-testing strategy 
Supplementary Figures 
 
  
 Supplementary Figure 1: Decision Analysis Model.  The right half of the model reflects a 
population based approach to testing from BRCA1, BRCA2, PALB2, RAD51C, RAD51D, 
BRIP1 and PALB2 mutations. The left half of the model reflects a clinical criteria/ family 
history based testing approach for the same. Each decision point in the model is called a 
‘node’ and each path extending from a node is called a decision ‘branch’. Each branch 
represents a mutually exclusive course or outcome. Each decision is given a probability 
highlighted along the decision branch. The probabilities (p1 to p29) used in the model are 
explained in Table 1 and Supplementary Table 1. The path probabilities are given for each 
branch of the model. Values for each outcome are calculated. Cancer incidence was estimated 
by summing the probabilities of pathways ending in ovarian or breast cancer. Final outcomes 
of each path include development of breast cancer (BC), ovarian cancer (OC), no 
breast/ovarian cancer (no OC or BC) and excess deaths from coronary heart disease (CHD).  
Abbreviations: BC- Breast Cancer, CHD- Coronary heart disease; OC-Ovarian Cancer; No 
OC or BC- No Ovarian Cancer or Breast Cancer developed., RRSO –Risk reducing salpingo-
oophorectomy; RRM – Risk reducing mastectomy; BRCA= BRCA1 & BRCA2; RAD+ = 
RAD51C, RAD51D & BRIP1 
 
 
 Supplementary Figure 2.  One way Sensitivity Analysis: Clinical-criteria/Family-history screening for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1and PALB2 mutations in UK women.  One-way sensitivity analysis for all probabilities, costs and utilities in terms of ICER 
of – UK Clinical-criteria/Family-history based screening for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 mutations, compared to a Clinical-
criteria / FH-based approach for BRCA1 and BRCA2 testing. Y-axis: Incremental cost-effectiveness ratio (ICER): Cost (£s) per quality adjusted 
life year (QALY) (discounted). X-axis: Probability, cost and utility parameters in the model. The model is run at both lower and upper 
values/limits of the 95% confidence interval or range of all probability parameters described in Table-1/methods; and both lower and upper 
values/limits of the cost and utility-score parameters given in Table 2. Costs are varied by +/- 30%. ‘Maximum value’ represents outcomes for 
upper limit and ‘minimum value’ represents outcomes for lower limit of the parameter.  
  
  
Supplementary Figure 3. One way Sensitivity Analysis: Clinical-criteria/Family-history screening for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations in USA women.  One-way sensitivity analysis for all probabilities, costs and utilities in terms of 
ICER of – USA Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 mutations, compared to a Clinical-criteria/ FH-
based approach for BRCA1 and BRCA2 testing.  Y-axis: Incremental cost-effectiveness ratio (ICER): Cost ($s) per quality adjusted life year 
(QALY) (discounted). X-axis: Probability, cost and utility parameters in the model. The model is run at both lower and upper values/limits of the 
95% confidence interval or range of all probability parameters described in Table-1/methods; and both lower and upper values/limits of the cost 
and utility-score parameters given in Table 2. Costs are varied by +/- 30%. ‘Maximum value’ represents outcomes for upper limit and ‘minimum 
value’ represents outcomes for lower limit of the parameter.  
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SUPPLEMENTARY TABLES 
 
SUPPLEMENTARY TABLE 1: DECISION ANALYSIS MODEL ASSUMPTIONS 
 
Detailed description of Model Assumptions: 
The decision-analysis model assumes all women in the population-screening arm and only 
those fulfilling clinical/FH-criteria in the FH-arm are offered genetic-counselling and 
genetic-testing. We assume 71% will uptake genetic-testing (from GCaPPS study) (1). 
The cost of pre-test counselling is included (2,3). BRCA1/BRCA2 negative women are 
tested for RAD51C/RAD51D/BRIP1/PALB2 mutations (from the same DNA sample). 
Genetic-testing is undertaken in a research laboratory with repeat confirmatory testing for 
all pathogenic mutations in identified carriers being performed in an accredited Health 
Service genetics laboratory. This approach has been accepted and is being currently 
implemented within the UK 100,000 genome project for delivering personalised medicine 
across the UK National Health Service (NHS) (4). This has also been adopted in a pilot 
study on acceptability of general population testing in the PROMISE-programme (5). In 
line with current guidelines/literature (6,7), women testing positive are offered RRSO to 
reduce their OC risk (8,9). BRCA1/BRCA2/PALB2 mutation carriers are also offered 
options for BC-risk reduction: MRI/mammography screening; chemoprevention with 
SERM (10) or RRM (11) to reduce their BC-risk as appropriate (7). The model 
incorporates the increased risk of cardiovascular mortality (absolute increase=3.03%) 
reported with pre-menopausal bilateral-oophorectomy, particularly in women <45-50years 
who don’t take hormone replacement therapy (HRT) (12,13). The increased risk of heart 
disease and associated costs are modelled over an individual’s lifetime. Women 
undergoing RRSO are given HRT till 51years. We assume HRT compliance of 
80%(CI:76%,83%) (14). We include costs of bone health monitoring using Dual Energy 
X-ray Absorptiometry (DEXA) scans as well as calcium and vitamin D3 and HRT 
supplementation. Short-term HRT following RRSO does not affect BC-risk (15). OC-
screening was excluded, as a conclusive mortality benefit has not been demonstrated (16). 
Model outcomes included OC, BC and excess deaths from coronary heart disease. As per 
National Institute of Health and Care Excellence(NICE) economic evaluation guidelines, 
costs and outcomes are discounted at 3.5% (17). 
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SUPPLEMENTARY TABLE 2. PROBABILITIES OF DIFFERENT PATHWAYS IN 
THE MODEL 
 
Prob
abilit
y  
Value (95%CI) [Range] Description  Source  
P1 0.00677 
(0.0059-
0.0077) 
BRCA1/BRCA2 mutation 
prevalence in a general 
population  
Jervis 2015 (18) 
P2 0.47 (0.34-0.56) Probability that carrier will undergo RRM 
Evans 2009 (19) 
P3 0.96 [0.8-0.96] Reduction in risk of ovarian cancer from RRSO 
Finch 2006 (8), 
Rebbeck 2009 (9) 
P4 0.202 [0.17-0.28] 
Probability that 
BRCA1/BRCA2 carrier without 
RRSO will get ovarian cancer 
Antoniou 2008 
BOADICEA (20), 
Chen 2007 (21) 
P5 
0.02 (0.001, 0.06) Probability that a non-carrier will get ovarian cancer 
CRUK 2015 (22) 
0.0128 (0.0126- 0.0130) 
Probability that a non-carrier 
will get ovarian cancer – USA 
estimate 
SEER (23) 
P6 0.0098 (0.0047, 0.0179) 
Probability of having a positive 
FH  fulfilling non-AJ genetic 
testing criteria 
ABCFR data 
P7 0.1  
BRCA1/BRCA2 prevalence in 
those fulfilling clinical criteria 
or FH positive  individuals 
Current testing 
guideline 
P8  0.0056 (0.0049, 
0.0066) 
BRCA1/2 Mutation prevalence 
in FH negative individuals 
Jervis 2015 (18), 
ABCFR data 
P9 0.911 (0.62-0.98) 
Reduction in breast cancer  risk 
from RRM without RRSO in 
BRCA1/2 carriers 
Rebbeck 2004 
(11) 
P10 0.644 [0.42-0.67] 
Probability that BRCA1/2 
carrier without RRM will get 
breast cancer 
Antoniou 2008 
BOADICEA (20), 
Chen 2007 (21) 
P11 
0.129 [0.11-0.14] 
Probability that a non-BRCA1/2 
carrier will get breast cancer 
with screening 
CRUK 2015 (22) 
0.124 (0.1236- 0.1249) 
Probability that a non-BRCA1/2 
carrier will get breast cancer 
with screening – USA estimate 
SEER (23) 
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P12 0.55 (0.30-0.75) 
Probability that mutation 
carrier will follow-up with 
RRSO 
Manchanda 2012 
(24) 
P13 0.49 (0.37-0.65) 
HR for breast cancer from 
RRSO alone in BRCA1/BRCA2 
carrier 
Rebbeck 2009 (9) 
P14 0.95 (0.78-0.99) 
Reduction in risk of breast 
cancer from RRM with RRSO 
in BRCA1/BRCA2 carriers 
Rebbeck 2004 
(11) 
P15 0.002 (0.0003, 0.0036) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in 
unselected general population 
controls 
Song 2015 (25), 
Ramus 2015 (26) 
P16 0.089 (0.05, 0.17) 
Probability that RAD51C, 
RAD51D, BRIP1 carrier 
without RRSO will get ovarian 
cancer  
Loveday 2012 
(27), Loveday 
2011 (28), Ramus 
2015 (26) 
P17 0.94 (0.83-0.98) 
Reduction in ovarian cancer 
risk from RRSO in RAD51C, 
RAD51D, BRIP1 
Parker 2013 (12) 
P18 0.62 (0.53-0.74) 
HR of breast cancer from 
RRSO alone in RAD51C, 
RAD51D, BRIP1 
Parker 2009 (29) 
P19 0.0122 (0.0074, 0.017) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
positive (BRCA1/2 negative) 
individuals 
Song 2015 (25), 
Ramus 2015 (26) 
P20 0.00186 
(0.00023, 
0.0034) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
negative individuals 
Song 2015 (25), 
Ramus 2015 (26) 
and ABCFR data 
P21 0.0303 (0.011,0.043) Risk of mortality from CHD after RRSO 
Parker 2013 (12) 
P22 0.8 (0.76,0.83) Compliance with HRT Read 2010 (14) 
P23 0.71 (0·60–0·83) HR of breast cancer risk from chemoprevention 
Cuzick 2015 (30) 
P24 0.163 (0.136, 0.19) Uptake of breast cancer chemoprevention 
Smith 2016 (31) 
P25 0.00125 
(0.0008, 
0.0017) 
PALB2 Mutation prevalence in 
unselected general population 
controls 
Slavin 2017 (32) 
P26 0.44 (0.34, 0.55) 
Probability that PALB2 carrier 
without RRM will get breast 
cancer 
Antoniou 2014 
(33) 
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P27 0.0089 (0.0079, 
0.0099) 
PALB2 Mutation prevalence in 
FH positive (BRCA1/2 negative) 
individuals 
Buys 2017 (34) 
P28 0.0012 (0.00073, 0.0016) 
PALB2 Mutation prevalence in 
FH negative individuals 
ABFCR data, 
Buys 2017 (34), 
Slavin 2017 (32) 
P29 0.0072 (0.0068, 0.0076) Excess risk of CHD after RRSO 
Parker 2013 (12) 
95%CI- 95% confidence interval, ABCFR- Australian Breast Cancer Family Registry, 
CHD- Coronary heart disease, CRUK- Cancer Research UK, FH- family history, HRT- 
hormone replacement therapy , RRSO- risk reducing salpingo-oophorectomy, RRM: Risk 
reducing Mastectomy, 
A detailed explanation of the various probabilities is given in Supplementary Table-S1 
Explanation: 
 
P1: The probability of carrying a BRCA1/BRCA2 mutation in the non-AJ population (P1= 
0.00677) is taken from Jervis et al 2015. It provides the most up to date estimates for 
BRCA1/BRCA2 prevalence using contemporary sequencing technologies and knowledge 
of pathogenicity (18).  
P2: The probability that BRCA1/2 carrier will undergo RRM is taken is taken from an 
analysis of UK BRCA1/2 carriers by Evans et al 2009 (19). A composite uptake rate 
(P2=0.47) for BRCA1 (60% RRM rate) and BRCA2 (43% RRM rate) carriers  weighted 
for the relative prevalence of BRCA1 and BRCA2 mutations was computed (19). 
P3: The reduction in ovarian cancer risk obtained from RRSO (P3= 0.96) is taken from 
previous studies which report a 4% residual-risk of primary peritoneal cancer following 
RRSO (8).  
P4: A wide range of ovarian cancer risks have been reported for BRCA1/BRCA2 carriers, 
with higher penetrance estimates found in carriers ascertained from high-risk families with 
multiple cancer cases (35). Our analysis uses ovarian cancer penetrance figures till age 80 
years from Antoniou 2008, which are corrected for ascertainment (20). To simplify the 
analysis we have used a composite risk for BRCA1 and BRCA2 carriers (P4= 0.202) 
weighted for the relative prevalence of BRCA1 and BRCA2 mutations.  
P5: The risk of ovarian cancer in a low-risk population is obtained from Cancer Research 
UK (22) for UK women and SEER (23) data for USA women. 
P6: the probability of having a positive FH fulfilling non-AJ genetic testing criteria is 
obtained from the unselected control population of the Australian Breast Cancer Family 
Registry database (unpublished data).  
P7: This is the BRCA1/2 mutation probability in FH positive individuals i.e., individuals 
who have a strong family history of cancer. P7=0.1 which is the threshold for genetic 
testing.  
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P8: The probability of BRCA1/2 Mutation prevalence in FH negative individuals 
(individuals without a strong family history of cancer who do not fulfil the threshold of 
genetic testing is estimated from population mutation prevalence (Jervis et al) (18) and 
Australian Breast Cancer Family Registry control data.  
P9: Reduction in breast cancer risk from RRM in BRCA carriers not undergoing RRSO is 
taken from the PROSE study data by Rebbeck et al, JCO 2004 (11). 
P10: The breast cancer penetrance estimates for BRCA1/BRCA2 carriers till age 80 years 
which are corrected for ascertainment are obtained from Antoniou 2008 (20). To simplify 
the analysis we have used a composite risk for BRCA1 and BRCA2 carriers (P10=0.644) 
weighted for the relative prevalence of BRCA1 and BRCA2 mutations.  
P11: The risk of breast cancer in a low risk population is taken from Cancer Research UK 
and UK Office for National Statistics data for UK women (22,36) and from SEER (23) data 
for USA women. 
P12: Decision making regarding RRSO can be a complex process. RRSO rates ranging 
from 0.3 to 0.75 have been reported in the literature (19,24,37,38). We have used the 
RRSO rate reported in high-risk women from London (P12= 0.55), as it reflects the views 
of carriers from a UK population and is within the range reported in the literature (24).  
P13: The reduction in breast cancer risk in pre-menopausal BRCA1/BRCA2 women 
undergoing RRSO alone is taken from a meta-analysis by Rebbeck et al 2009 (9).  
P14: Reduction in breast cancer risk in BRCA1/BRCA2 women undergoing RRM and 
RRSO is taken from the PROSE study data by Rebbeck et al 2004 (11). 
P15: The mutation prevalence RAD51C, RAD51D, BRIP1 in unselected general 
population controls is obtained from recent publications by Song et al 2015 (RAD51C, 
RAD51D) (25) and Ramus et al 2015 (BRIP1) (26). A composite prevalence for all three 
mutations is calculated. 
P16: The ovarian cancer penetrance for RAD51C, RAD51D, and BRIP1 mutations is 
obtained from recent publications by Loveday 2011 (RAD51D) (28), Loveday 2012 
(RAD51C) (27) and Ramus 2015 (BRIP1) (26). A composite penetrance weighted for the 
relative prevalence of RAD51C, RAD51D, and BRIP1 mutations was computed. 
P17: Reduction in ovarian cancer risk from RRSO in RAD51C, RAD51D, BRIP1 carriers 
is obtained from risk reduction observed in the general population (non-BRCA1/BRCA2 
carriers) reported by Parker 2013 (12), as no specific data for RAD51C, RAD51D, BRIP1 
exist.  
P18: Reduction in breast cancer risk from RRSO in RAD51C, RAD51D, BRIP1 carriers is 
obtained from risk reduction observed in the general population (non-BRCA1/BRCA2 
carriers) reported by Parker (29), as no specific data for RAD51C, RAD51D, BRIP1 exist. 
P19: RAD51C, RAD51D, BRIP1 mutation prevalence in FH positive (BRCA1/2 negative 
individuals with a strong family history of cancer) is obtained from UKFOCSS data (Song 
2015, Ramus 2015) (25,26). 
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P20: RAD51C, RAD51D, BRIP1 mutation prevalence in FH negative individuals (those 
with a strong family history of cancer) is obtained from Song 2015, Ramus 2015 (25,26) 
and Australian Breast Cancer Family Registry control data.  
P21: The risk of CHD mortality is obtained from the Nurses Health Study (Parker et al 
2013) (12). Death from CHD is reported in 1 in 33 pre-menopausal women undergoing 
RRSO and not taking HRT (12). 
P22: HRT compliance rate is obtained from a UK cohort (Read et al, 2010) (14). 
P23: The level of breast cancer risk reduction obtained from chemoprevention in high risk 
women is obtained from the recent published extended long term follow-up of the IBIS-I 
breast cancer prevention trial. The HR of breast cancer is reported as 0.71 (0·60–0·83)  
(Cuzick et al 2015)(30). 
P24: the breast cancer chemoprevention uptake rate is obtained from a recent meta-analysis 
by Smith et al meta-analysis. The pooled uptake estimate was 16.3% [95% CI 13.6%–
19.0%] (31). 
P25: The probability of carrying a PALB2 mutation in the general population is taken from 
control data used in a study by Slavin 2017 (32). 
P26: The breast cancer penetrance estimates for PALB2 carriers till the age 80 years are 
obtained from Antoniou 2014 (33). 
P27: Mutation prevalence of PALB2 in FH positive carriers is obtained from a study of 
35,000 women with breast cancer by Buys 2017 (34). 
P28: Australian Breast Cancer Family Registry control data along with population 
prevalence estimates above inform the PALB2 mutation prevalence in FH negative 
carriers. 
P29: Excess risk of CHD after oophorectomy is estimated using data from Parker 2013 
(12). The absolute excess CHD incidence is obtained by subtracting CHD in women with 
oophorectomy from those without oophorectomy. 
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SUPPLEMENTARY TABLE 3. SUMMARY OF COSTS USED IN MODEL (2015 
PRICES)* 
Item Cost UK (£) 
Cost 
USA ($) Source 
Cost of genetic testing  175 330 
PROMISE programme and NHS clinical 
genetics laboratory 
Cost of counselling  27 43 
GCaPPS (1,2), PSSRU Unit costs of 
Health and Social Care (39), Schwartz et 
al 2014 (3), Eggington 2014 (40). 
Cost of RRSO (and HRT 
and osteoporosis 
prevention) 
3,570 8,144 
NHS Reference costs (41), BNF (42), 
Grann 2011 (43), Williams-Frame 2009 
(44)  
Cost of ovarian cancer 
diagnosis and initial 
treatment 
14,201 127,995 
NHS Reference costs (41), NICE 
guideline (45), Grann 2011 (43) 
Yearly cost of ovarian 
cancer treatment and 
follow-up: years 1-2 
5,394 14,071 
NHS Reference costs (41), NICE 
guideline (45), Grann 2011 (43), CRUK 
2014 report (46) 
Yearly cost of ovarian 
cancer treatment  and 
follow-up: years 3-5 
5,024 14,071 
NHS Reference costs (41), NICE 
guideline (45), Grann 2011 (43), CRUK 
2014 report (46) 
Terminal care cost with 
ovarian cancer 
15,588 89,424 
National Audit office (47), Grann 2011 
(43)  
Cost of breast cancer 
screening general  
350 1534 
Robertson 2011 (48), NHS reference cost 
(41), CDC guideline (49) 
Cost of breast cancer 
screening 
BRCA1/BRCA2/PALB2 
carriers  
 
4,623 
 
33,530 
NHS reference cost (41), NICE guideline 
Familial breast cancer (7), CDC 
guidelines (49), Grann 2011 (43) 
Cost of RRM  4,059 12,596 
NHS reference cost (41), weighted for 
21% complication rate (6,50), Grann 
2011(43)  
Cost of breast cancer 
diagnosis and treatment 
(Sporadic, PALB2) 
15,923 
 
82,030 
 
NHS Reference costs (41), NICE 
guideline Advanced breast cancer (51), 
NICE guidelines Early and locally 
advanced breast cancer (52), 
Grann 2011 (43) 
Cost of breast cancer 
diagnosis and treatment 
(BRCA1/BRCA2) 
14,476 75,873 
NHS Reference costs (41), NICE 
guideline Advanced breast cancer (51), 
NICE guidelines Early and locally 
advanced breast cancer (52), 
Grann 2011 (43) 
14 
 
Yearly cost of breast 
cancer follow-up and 
adjuvant treatment if any 
(e.g. Tamoxifen): years 
1-5 (Sporadic breast 
cancer) 
2,027 7,738 
BNF (42), Robertson 2011 (48), NHS 
Reference costs (41),  
NICE guidelines Early and locally 
advanced breast cancer (52),  
NICE guideline Advanced breast cancer 
(51).   
National Costing report. Implementing 
NICE guidance 2009 (53), 
Grann 2011 (43) 
Yearly cost of breast 
cancer  follow-up and 
adjuvant treatment if any 
(e.g. Tamoxifen): years 
1-5 (BRCA1,BRCA2) 
1,748 7,738 
BNF (42), Robertson 2011 (48), NHS 
Reference costs (41)  
NICE guidelines Early and locally 
advanced breast cancer (52)  
NICE guideline Advanced breast cancer 
(51)   
National Costing report. Implementing 
NICE guidance 2009 (53) 
Grann 2011 (43) 
Yearly cost of breast 
cancer  follow-up and 
adjuvant treatment if any 
(e.g. Tamoxifen): years 
1-5 (PALB2) 
1,852 7738 
BNF (42), Robertson 2011 (48), NHS 
Reference costs (41) Antnoiou 2014 (33),  
NICE guidelines Early and locally 
advanced breast cancer (52),  
NICE guideline Advanced breast cancer 
(51),   
National Costing report. Implementing 
NICE guidance 2009 (53), 
Grann 2011 (43) 
Terminal care cost with 
breast cancer 
15,588 65,403 Grann 2011 (43) 
Cost of fatal CHD 3,343 23,012 
NHS Reference costs (41,47), Afana 
2015 (54) 
Cost of excess CHD 3,380 188,787 
NIH (55), Townsend 2015 (56), CDC 
2017 (57), Parker 2013 (12), American 
Heart Association 2017 (58), World Bank 
2017 (59) 
 
*All costs were varied by +/-30% in one way sensitivity analysis 
BNF- British National Formulary, CDC- Centers for Disease Control and Prevention, 
CHD- Coronary heart disease, GCaPPS- Genetic Cancer Prediction through Population 
Screening study, HRT- hormone replacement therapy, NHS- National Health Service, 
NICE-National Institutes for Health and Care Excellence, PSSRU- Personal Social 
Services Research Unit, RRSO- risk reducing salpingo-oophorectomy, RRM- risk reducing 
mastectomy, UK- United Kingdom, USA- United States of America 
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Costs obtained from Grann 2011 were inflated using the medical component of the USA 
consumer price index to 2015 US$. 
 
A detailed explanation of the costs is given in Supplementary Table-S2 
 
Explanation 
 
Cost of genetic counselling/ testing: based on pre-test counselling in the population based 
GCaPPS study, 71% genetic testing uptake (GCaPPS study). The UK national unit cost 
assumed for genetic counseling= £44/hr of client contact from PSSRU Unit costs of Health 
and Social Care 2010 (1,2,39). The USA costs of genetic counselling are taken from 
Schwartz et al 2014, which includes ancillary preparation (scheduling/administration), 
counsellor preparation and counselling (3). We also include the cost of post-test 
counselling for VUS in 2% cases (40). 
The cost of BRCA1/BRCA2 and RAD51C, RAD51D, BRIP1 and PALB2 testing is based 
on testing costs for these genes in the PROMISE research programme as well as 
confirmatory testing costs in an accredited national genetics laboratory for those testing 
positive.  
 
RRSO costs: UK costs are based on national reference costs for an upper genital tract 
laparoscopic/endoscopic intermediate procedure (41), and USA costs are from Grann 2011 
(43) which were inflated using the medical component of the USA consumer price index to 
2015 US$. Costs of HRT for the UK are taken from BNF (42) and for the USA from 
Williams-Frame 2009 (44). Costs assume HRT is given from average age of RRSO to the 
average age of menopause (51 years). These costs are calculated for the 80% assumed to be 
compliant with HRT. Costs include the cost of three follow up DEXA scans for monitoring 
bone health and calcium and vitamin-D3 for additional osteo-protection. 
 
Ovarian Cancer Costs: 
We assumed that the cost of diagnosis to include a pelvic examination, ultrasound scan, 
CA125 test, CT scan, percutaneous biopsy and peritoneal cytology.  
The cost of treatment included the reference cost for a lower and upper genital tract very 
complex major procedure and administration of chemotherapy based on 6 cycles of 
carboplatin and paclitaxel treatment. It was assumed that in years-1 and -2 treated survivors 
would have a further three consultant visits, a CT scan and 4 CA125 tests each year. In 
years 3 to 5 post-surgery it was assumed that survivors would have 2 consultant visits and 
2 CA125 tests.  
Costs for ovarian cancer diagnosis and treatment in the UK were derived from national 
reference costs and a recent ovarian cancer guideline developed by NICE (41,45). Annual 
costs of ovarian cancer treatment in the USA are taken from Grann et al 2011 (43), and 
inflated using the medical component of the USA consumer price index to 2015 US$. 
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We include costs of treatment of recurrence, taken from the Saving lives, averting costs 
report commissioned by CRUK (46) and Grann 2011 (43). 
 
Costs for terminal care for ovarian cancer in the UK were derived from end-of-life costs 
for cancer patients based on a report from the National Audit Office (47). Terminal care 
costs for ovarian cancer in the USA are obtained from Grann, 2011 (43), and inflated using 
the medical component of the USA consumer price index to 2015 US$. 
In line with NICE recommendations future healthcare costs not associated with ovarian 
cancer were not considered (17). 
Breast Cancer Costs: 
Breast cancer diagnosis & treatment costs are predominantly derived from: ‘National 
costing report- Implementing NICE guidance (Feb 2009)’ which provides estimates of the 
national cost impact arising from implementation of NICE guidelines for diagnosis and 
treatment of early/locally advanced breast cancer and advanced breast cancer in England, 
UK (53); from UK Department of Health NHS reference costs 2012 (41); the BNF (42), 
and other relevant NICE guidelines on breast cancer care in general and high risk 
populations (7,51,52). 
 
Cost of breast cancer screening for non-carriers: assumes routine mammography (8 
mammograms between 50-70 years) as per UK NHS breast cancer screening program (60). 
Breast screening in the USA assumes mammography every two years starting at 50 years 
(49). 
Cost of breast screening for BRCA1/2 carriers: for the UK it is based on annual 
mammogram from 40-69 years and annual MRI from 30-49 years  as per NICE guidelines 
for familial breast cancer (7). For the USA it is based on yearly mammography and MRI 
starting at 30 years, then the cost of annual mammography only from age 50 years (49). 
 
Cost of RRM: obtained from NHS reference costs (41) weighted for a 21% complication 
rate (6,50). For the USA this is obtained from Grann 2011 (43), and inflated using the 
medical component of the USA consumer price index to 2015 US$. 
 
Cost of breast cancer treatment: In the general population 10% breast cancer is non-
invasive DCIS; 90% breast cancer is invasive; 95% of invasive breast cancer is early and 
locally advanced (41% Stage-1, 45% stage-2, 9% stage-3 (53,61-63)); 5% of invasive 
breast cancer is advanced breast cancer (stage 4) (53,61,62); 35% of early & locally 
advanced breast cancer will progress to advanced breast cancer (NICE costing report, 
2009) (53). In BRCA1/2 carriers, 20% of cancers are DCIS and 80% invasive (61% stage1)  
(6,64). 
Stage distribution in PALB2 carriers was assumed to be the same as in the general 
population, owing to a lack of robust PALB2 specific data. 
 
The cost of diagnosis includes clinical examination, mammogram, ultrasound & biopsy. 
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Mean prevalence of Axillary lymph node metastasis in early invasive breast cancer is 
31.4% (systematic reviews within the NICE breast cancer guideline (52) and breast cancer 
clinical outcome measures (BCCOM) project (65)). 30% node positive rate is assumed for 
BRCA1/2 breast cancer (based on screening studies in familial breast cancer, breast cancer 
case series and Early Breast Cancer Trialists’ Collaborative Group data) (64,66-69). 
Annual breast cancer treatment costs in the USA are obtained from Grann et al 2011 (43), 
and inflated using the medical component of the USA consumer price index to 2015 US$. 
 
Cost of Sentinel lymph node biopsy (SLNB): is obtained from NICE national costing 
report (53). SLNB is used for staging axilla for early invasive breast cancer and no 
evidence of lymph node involvement on Ultrasound (US)/ negative US-guided biopsy 
(73% of invasive cancers). 
Cost of axillary lymph node dissection (ALND): is assumed to be 25% of cost of breast 
surgery as per NICE guideline development group recommendation (53). ALND is 
undertaken for lymph node positive cancers (31% early & locally advanced invasive 
cancers) (52,53).  
 
Breast Surgery Costs: This includes, costs of breast conserving surgery (assumed for all 
non-invasive cancers, and 75% of early/locally advanced (stage 1-3) invasive cancers); and 
costs of mastectomy with reconstruction (for 25% early/locally advanced cancers). Costs 
are obtained from the national NHS reference costs (41). 
Radiotherapy and Chemotherapy: Invasive breast cancers who are not low risk (65,70,71) 
receive adjuvant treatment in line with NICE guidelines. Costs include, radiotherapy costs 
for 60% of early invasive/locally advanced, radiotherapy and chemotherapy costs for 40% 
early invasive/locally advanced and chemotherapy costs for all advanced cancers. 
Radiotherapy costs include planning and 40Gy in 15 fractions over 3 week (NICE 
guidelines (52)) or palliative treatment, taken form national NHS reference costs (72). 
Chemotherapy costs based on polychemotherapy (66), include administration costs, costs 
of 1st and 2nd line therapy and toxicity from NICE guidelines (51,53).  
All costs are adjusted for BRCA1/2 breast cancers for difference in stage at presentation & 
20% cancers being non-invasive.  
70% general population invasive breast cancers are ER positive; 15% early invasive breast 
cancers and 25% advanced breast cancers are HER2 positive (51,52). 27% BRCA1 and 
67% BRCA2 breast cancers are ER positive; 5% BRCA1 and 14% BRCA2 breast cancers 
are HER2 positive (67-69,73-75). ER & HER2 testing costs are obtained from a local NHS 
trust and included for all breast cancers. 74% of PALB2 breast cancers are ER positive 
(33).  
Endocrine therapy costs: As per NICE guidelines (52,53), ER positive invasive breast 
cancers receive Tamoxifen 20mg/day (premenopausal)/ Anastrazole 1mg/day 
(postmenopausal) for 5 years: costed from the BNF (42). Rates are adjusted for BRCA1/2 
and PALB2 carriers, ER positivity and menopause status. 
Biphosphonate costs: 74% patients with advanced breast cancer will develop bone 
metastases and 65% patients with bone metastases are offered bisphosphonates (53,76,77). 
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As per NICE guidelines, costs (from BNF(42)) assume that 50% patients receive oral 
clodronate & ibandronic acid, and 50% receive intravenous zoledronic acid or pamidronate 
(53). 
Cost of Trastuzumab: For HER2 positive patients, given at 3-week intervals for 1 year or 
until disease recurrence as per NICE guidelines. Costs obtained from NICE costing report 
(53). 
35% of early/locally advanced breast cancer progress to advanced breast cancer (NICE 
guidelines) (53). Recurrence rates for early/locally advanced breast cancer (from the USA 
National Surgical Adjuvant Breast and Bowel Project (NSABP)):  15.9% for node positive 
(78) and 11% for node negative (79) breast cancer: composite recurrence rate= 12.6% 
(weighted for 31% node positive and 69% node negative disease). Recurrence rate for 
advanced/metastatic breast cancer is 66% (34% relapse free 5yr survival) (80). 
Follow up Costs: Includes annual mammograms and six monthly consultations. MRI scan 
for all stage 4 cancers. Costs include a progression rate of 35% from early & locally 
advanced to advanced disease (53), and 66% relapse rate for advanced disease (80). 
 
Costs for terminal care for breast cancer were derived from end-of-life costs for cancer 
patients based on a report from the National Audit Office, UK (47). For the USA terminal 
care costs are obtained from Grann 2011 (43), and inflated using the medical component of 
the USA consumer price index to 2015 US$. 
In line with NICE recommendations future healthcare costs not associated with breast 
cancer were not considered (17). 
 
Chemoprevention: Tamoxifen/Raloxifene for 10 years (7,10), from BNF (UK) (42) and 
Grann et al 2011 (USA) (43). 16.3% uptake was assumed for chemoprevention (31). 
 
Cost of CHD: 
Cost of excess CHD: British Heart Foundation statistics reports costs per capita across four 
Commissioning Regions in England (London, Midlands and East, North and South) (56). 
The costs of CHD and stroke are averaged across the four regions. The prevalence of CHD 
is estimated at 12.0% in the UK (56) and 11.7% in the USA (57) with the onset of CHD 
estimated at 55 years of age (12,55). 
 
The yearly cost of CHD in the UK is obtained by dividing the per capita cost by the 
population prevalence of CHD (56). Using the report published by the American Heart 
Association (58), the total cost of CHD, CHF and stroke were divided by the population 
with CHD (57,59) giving the yearly cost of CHD in the USA. This yearly cost is multiplied 
by the number of years between onset of CHD and average life expectancy to provide the 
cost attributed to excess CHD. 
 
Cost of fatal CHD: This was costed on the basis of a fatal myocardial infarction using NHS 
reference costs (41). USA costs are obtained from Afana et al 2015 (54).  
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SUPPLEMENTARY TABLE 4. ESTIMATES FOR AGE OF ONSET AND 
SURVIVAL FOR BREAST AND OVARIAN CANCERS 
 
  
 
The analysis has a lifetime time horizon covering lifetime risks as well as long-term 
consequences. Female life-tables from the Office of National-Statistics (UK-women) and 
SEER (USA-women) were used  for life-expectancy data for women who did not 
develop OC/ BC (81). 
To simplify the analysis we used average ages for BC (44.4 years) and OC (59.6 years) 
onset for BRCA1/BRCA2 carriers (82). These were obtained by assigning weights to the 
individual ages of onset for the relative population prevalence of BRCA1 and BRCA2 
((0.00158*AgeBRCA1)/0.00677 + (0.00519*AgeBRCA2)/0.00677)).   The median ages of 
onset of sporadic OC/BC were 68/60 and 63/62 years in the UK and USA populations 
respectively (from CRUK, SEER) (83-85). OC/BC outcomes were modelled using 10-
year survival data.  
No statistically significant survival difference between BRCA1/BRCA2 and sporadic BC 
has been reported (86,87).  For BC, 10-year survival rate=78.4% (CI: 78.3,78.4) (88). 
Long-term survival outcomes for BRCA and sporadic OC have also recently been 
reported to be similar (89).  For OC the 10 year survival rates for BRCA1 and BRCA2 
are 34% and 28% respectively (89,90). Composite survival rates for BRCA1+BRCA2 
OC are calculated by weighting the individual survival rates for the relative population 
prevalence of BRCA1 and BRCA2 ((0.00158*OC-SurvivalBRCA1)/0.00677 + 
(0.00519*OC-SurvivalBRCA2)/0.00677)). This gives composite BRCA1+BRCA2 survival 
rate at 10-years of 29%. For non-BRCA1/BRCA2 OC or sporadic OC: 10-year  
survival=34.5% (CI: 33.8,35.3) (91). After 10-years survival the probability of death was 
assumed to be the same as the general population.  
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SUPPLEMENTARY TABLE 5. UTILITY SCORES  
Detailed Explanation of Utility Scores used in the analysis 
QALY= (Survival in life-years) x (Utility-weight). Calculating QALYs requires 
knowledge of utility-weights for each health state in the model. ‘Utility-weight’ is an 
adjustment for quality-of-life. It indicates an individual’s preference for specific health 
state where ‘1’=perfect health and ‘0’= death. 
The utility-weight for RRSO= 0.95 (SD=0.1, Grann, 2010) (92) and for ovarian cancer 
(OC) treatment were obtained from Havrilesky, 2009 (93). We preferred Time-Trade-
Off (TTO) scores for comparing health state preferences as visual scales are generally 
less accurate due to inherent biases.(94) Utility-score for early stage OC= 0.81 
(SD=0.26) while for advanced stage OC (70% women at presentation)= 0.55 (SD=0.29) 
(93,95,96). The end-stage of life utility-score (where OC patients don’t survive the next 
year)= 0.16 (SD=0.25). Of those surviving initial chemotherapy, with early disease the 
chance of recurrence=10.5% annually,(97) and for advanced disease=20.6% annually 
(95). For women with recurrent disease the mean utility-score=0.5 (range=0.4-0.61) and 
for remission it’s= 0.83 (SD=0.25) (93).   
 
Of general population Breast Cancer (BC), 10%= non-invasive/DCIS; 90%= invasive; 
95% of invasive cancer is early & locally advanced (41%= Stage-1, 45%=stage-2, 
9%=stage-3)(53,61-63) and 5%=advanced (stage-4) (53,61,62).  
In BRCA associated BC, 20%= DCIS and 80%= invasive (61%= stage1) (6,64). Utility-
weights for BC were obtained from NICE guidelines (51,98)  and assumed as follows: 
advanced BC= 0.65, early/locally advanced BC= 0.71, remission= 0.81 and recurrence= 
0.45. For those who survived initial chemotherapy, the chance of BC 
recurrence/progression with early/locally advanced disease= 35% (53) and for 
recurrence with advanced disease= 66% (80). 
 
 
 
  
21 
 
References 
1. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer 
predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized 
controlled trial. J Natl Cancer Inst 2015;107(1):379. 
2. Manchanda R, Burnell M, Loggenberg K, et al. Cluster-randomised non-inferiority 
trial comparing DVD-assisted and traditional genetic counselling in systematic population 
testing for BRCA1/2 mutations. J Med Genet 2016; 10.1136/jmedgenet-2015-103740. 
3. Schwartz MD, Valdimarsdottir HB, Peshkin BN, et al. Randomized noninferiority 
trial of telephone versus in-person genetic counseling for hereditary breast and ovarian 
cancer. J Clin Oncol 2014;32(7):618-26. 
4. Genomics England. The 100,000 Genomes Project. 2015, 
http://www.genomicsengland.co.uk/the-100000-genomes-
project/:http://www.genomicsengland.co.uk/the-100000-genomes-project/. 
http://www.genomicsengland.co.uk/the-100000-genomes-project/. 
5. PROMISE - Predicting Risk of Ovarian Malignancy, Improved Screening and Early 
detection. 2016, https://eveappeal.org.uk/our-research/our-research-programmes/promise-
2016/:https://eveappeal.org.uk/our-research/our-research-programmes/promise-2016/. 
https://eveappeal.org.uk/our-research/our-research-programmes/promise-2016/. 
6. Nelson HD, Fu R, Goddard K, et al. In. Risk Assessment, Genetic Counseling, and 
Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive 
Services Task Force Recommendation. Rockville (MD); 2013. 
7. NICE. Familial breast cancer: Classification and care of people at risk of familial 
breast cancer and management of breast cancer and related risks in people with a family 
history of breast cancer. In. NICE clinical guideline CG164 ed. London, UK: National 
Institute for Health and Care Excellence; 2013. 
8. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, 
fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Jama 
2006;296(2):185-92. 
9. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates 
associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation 
carriers. J Natl Cancer Inst 2009;101(2):80-7. 
22 
 
10. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in 
prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 
2013;381(9880):1827-34. 
11. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces 
breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin 
Oncol 2004;22(6):1055-62. 
12. Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with 
oophorectomy compared with ovarian conservation in the nurses' health study. Obstet 
Gynecol 2013;121(4):709-16. 
13. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after 
early bilateral oophorectomy. Menopause 2009;16(1):15-23. 
14. Read MD, Edey KA, Hapeshi J, et al. Compliance with estrogen hormone 
replacement therapy after oophorectomy: a prospective study. Menopause Int 2010;16(2):60-
4. 
15. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement 
therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 
and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23(31):7804-10. 
16. Jacobs I. Screening for familial ovarian cancer: the need for well-designed 
prospective studies. J Clin Oncol 2005;23(24):5443-5. 
17. NICE. Guide to the methods of technology appraisal. In. N1618 ed. London: National 
Institute for Health and Clinical Excellence (NICE); 2008. 
18. Jervis S, Song H, Lee A, et al. A risk prediction algorithm for ovarian cancer 
incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet 
2015; 10.1136/jmedgenet-2015-103077. 
19. Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected 
women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer 
Epidemiol Biomarkers Prev 2009;18(8):2318-24. 
20. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic 
susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 
2008;98(8):1457-66. 
21. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin 
Oncol 2007;25(11):1329-33. 
22. CRUK. Cancer incidence for common cancers. The 10 Most Common Cancers in 
Females, UK, 2012, 2015, http://www.cancerresearchuk.org/content/cancer-incidence-for-
23 
 
common-cancers#heading-Two:http://www.cancerresearchuk.org/content/cancer-incidence-
for-common-cancers#heading-Two. http://www.cancerresearchuk.org/content/cancer-
incidence-for-common-cancers#heading-Two. 
23. SEER. Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and 
Race/Ethnicity. 2016, 
https://seer.cancer.gov/csr/1975_2013/results_merged/topic_lifetime_risk.pdf 
https://seer.cancer.gov/csr/1975_2013/results_merged/topic_lifetime_risk.pdf 
https://seer.cancer.gov/csr/1975_2013/results_merged/topic_lifetime_risk.pdf  
24. Manchanda R, Burnell M, Abdelraheim A, et al. Factors influencing uptake and 
timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a 
competing risk time to event analysis. BJOG : an international journal of obstetrics and 
gynaecology 2012; 10.1111/j.1471-0528.2011.03257.x. 
25. Song H, Dicks E, Ramus SJ, et al. Contribution of Germline Mutations in the 
RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol 
2015;33(26):2901-7. 
26. Ramus SJ, Song H, Dicks E, et al. Germline Mutations in the BRIP1, BARD1, 
PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst 2015;107(11). 
27. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer 
susceptibility to ovarian cancer. Nat Genet 2012;44(5):475-6; author reply 476. 
28. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer 
susceptibility to ovarian cancer. Nat Genet 2011;43(9):879-82. 
29. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of 
hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 
2009;113(5):1027-37. 
30. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: 
extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 
2015;16(1):67-75. 
31. Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast 
cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 2016;27(4):575-
90. 
32. Slavin TP, Maxwell KN, Lilyquist J, et al. The contribution of pathogenic variants in 
breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 2017;3:22. 
33. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with 
mutations in PALB2. N Engl J Med 2014;371(6):497-506. 
24 
 
34. Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast 
cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 2017;123(10):1721-
1730. 
35. Evans DG, Shenton A, Woodward E, et al. Penetrance estimates for BRCA1 and 
BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of 
breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 
2008;8:155. 
36. ONS. Cancer Registration Statistics, England, 2011. Office for National Statistics, 
2013, http://www.ons.gov.uk/ons/dcp171778_315795.pdf. 
http://www.ons.gov.uk/ons/dcp171778_315795.pdf. 
37. Bradbury AR, Ibe CN, Dignam JJ, et al. Uptake and timing of bilateral prophylactic 
salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 
2008;10(3):161-6. 
38. Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and 
salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin 
Genet 2010;77(4):342-9. 
39. Curtis L. Unit Costs of Health and Social Care 2010. In: Personal Social Services 
Research Unit (PSSRU); 2010. 
40. Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory-based 
program for classification of variants of uncertain significance in hereditary cancer genes. 
Clin Genet 2014;86(3):229-37. 
41. Department of Health. NHS Reference Costs 2012-2013. 2013, 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261154/nhs_re
ference_costs_2012-
13_acc.pdf:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/26
1154/nhs_reference_costs_2012-13_acc.pdf. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261154/nhs_re
ference_costs_2012-13_acc.pdf. 
42. BNF. British National Formulary 67. London, UK: BMJ Group, and the 
Pharmaceutical Press (Royal Pharmaceutical Society of Great Britain); 2014. 
43. Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and 
prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 
2011;125(3):837-47. 
25 
 
44. Williams-Frame A, Carpenter JS. Costs of hormonal and nonhormonal prescription 
medications for hot flashes. Womens Health (Lond) 2009;5(5):497-502. 
45. NICE. Ovarian cancer: the recognition and initial management of ovarian cancer. In. 
London: National Institute for Health and Clinical Excellence (NICE); 2011. 
46. Incisive Health and Cancer Research UK. Saving lives, averting costs. An analysis of 
the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer 
2014, 
http://www.cancerresearchuk.org/sites/default/files/saving_lives_averting_costs.pdf:https://w
ww.incisivehealth.com/uploads/Saving%20lives%20averting%20costs.pdf  date accessed 
20/03/2017. 
http://www.cancerresearchuk.org/sites/default/files/saving_lives_averting_costs.pdf. 
47. NAO. End of life care. In: Burr TCaAG, (ed). London: National Audit Office (NAO), 
House of Commons; 2008. 
48. Robertson C, Arcot Ragupathy SK, Boachie C, et al. The clinical effectiveness and 
cost-effectiveness of different surveillance mammography regimens after the treatment for 
primary breast cancer: systematic reviews registry database analyses and economic 
evaluation. Health Technol Assess 2011;15(34):v-vi, 1-322. 
49. CDC. Breast Cancer Screening Guidelines for Women. 2016, 
https://www.cdc.gov/cancer/breast/pdf/breastcancerscreeningguidelines.pdf:https://www.cdc.
gov/cancer/breast/pdf/breastcancerscreeningguidelines.pdf. 
https://www.cdc.gov/cancer/breast/pdf/breastcancerscreeningguidelines.pdf. 
50. Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of 
prophylactic mastectomy followed by immediate breast reconstruction in women at 
hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line 
mutation. Eur J Surg Oncol 2002;28(6):627-32. 
51. NICE. Clinical Guideline (CG81) – Advanced breast cancer: diagnosis and treatment. 
In. Cardiff, Wales, UK: National Collaborating Centre for Cancer, National Institute for 
Health and Clinical Excellence; 2009. 
52. NICE. Early and locally advanced breast cancer: diagnosis and treatment. In. NICE 
Clinical Guideline, CG80. Cardiff, Wales, UK: National Collaborating Centre for Cancer, 
National Institute for Health and Clinical Excellence; 2009. 
53. NICE. National costing report: Early and locally advanced breast cancer/Advanced 
breast cancer. In. London, UK: National Institute for Health and Clinical Excellence; 2009. 
26 
 
54. Afana M, Brinjikji W, Cloft H, et al. Hospitalization costs for acute myocardial 
infarction patients treated with percutaneous coronary intervention in the United States are 
substantially higher than Medicare payments. Clin Cardiol 2015;38(1):13-9. 
55. NIH. Who Is at Risk for Coronary Heart Disease? , 
2016:https://www.nhlbi.nih.gov/health/health-topics/topics/cad/atrisk date accessed: 
10/08/2017. 
56. Townsend N, Bhatnagar P, Wilkins E, et al. Cardiovascular disease statistics. In: 
Hicks E, (ed). London, UK: British Heart Foundation; 2015. 
57. CDC. Heart Disease. 2017:https://www.cdc.gov/nchs/fastats/heart-disease.htm date 
accessed: 10/08/2017. 
58. American Heart Association. Cardiovascular Disease: A Costly Burden for America 
— Projections through 2035. 2017, http://www.heart.org/idc/groups/heart-
public/@wcm/@adv/documents/downloadable/ucm_491543.pdf. 
http://www.heart.org/idc/groups/heart-
public/@wcm/@adv/documents/downloadable/ucm_491543.pdf. 
59. The World Bank. Population, total. United Nations Population Division World 
Population Prospects, U.S. Census Bureau: Internation Database. , 2017, 
http://data.worldbank.org/indicator/SP.POP.TOTL. 
http://data.worldbank.org/indicator/SP.POP.TOTL. 
60. Waldron J. Breast Screening Programme, England 2008-09. In. UK: The NHS 
Information Centre, for Health and Social Care, Government Statistical Service; 2010. 
61. Lyratzopoulos G, Abel GA, Barbiere JM, et al. Variation in advanced stage at 
diagnosis of lung and female breast cancer in an English region 2006-2009. Br J Cancer 
2012;106(6):1068-75. 
62. CRUK. Breast Cancer Incidence Statistics UK 2009-2011. Breast Cancer (C50), 
Average Number of New Cases per Year and Age-Specific Incidence Rates, Females, UK, 
2009-2011, 2012, http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/incidence/uk-breast-cancer-incidence-statistics. 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/uk-breast-
cancer-incidence-statistics. 
63. ONS. Registrations of cancer diagnosed in 2006, England. Cancer Statistics 
Registrations, The Office for National Statistics, 2008, 
http://www.ons.gov.uk/ons/publications/index.html?newquery=cancer+statistics+registration
s&newoffset=50&pageSize=50&content-type=Article&content-type=Book&content-
27 
 
type=Journal&content-type=Report&content-type=Statistical+bulletin&content-type-
orig=publicationContentTypesOriginal&sortBy=none&sortDirection=none&applyFilters=tru
e. 
http://www.ons.gov.uk/ons/publications/index.html?newquery=cancer+statistics+registration
s&newoffset=50&pageSize=50&content-type=Article&content-type=Book&content-
type=Journal&content-type=Report&content-type=Statistical+bulletin&content-type-
orig=publicationContentTypesOriginal&sortBy=none&sortDirection=none&applyFilters=tru
e. 
64. Heijnsdijk EA, Warner E, Gilbert FJ, et al. Differences in natural history between 
breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-
MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 
2012;21(9):1458-68. 
65. Bates T, Kearins O, Monypenny I, et al. Clinical outcome data for symptomatic breast 
cancer: the Breast Cancer Clinical Outcome Measures (BCCOM) Project. Br J Cancer 
2009;101(3):395-402. 
66. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence 
and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-
717. 
67. Cortesi L, Turchetti D, Marchi I, et al. Breast cancer screening in women at increased 
risk according to different family histories: an update of the Modena Study Group experience. 
BMC Cancer 2006;6:210. 
68. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging 
and mammography of a UK population at high familial risk of breast cancer: a prospective 
multicentre cohort study (MARIBS). Lancet 2005;365(9473):1769-78. 
69. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome 
following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status 
and administration of adjuvant treatment. Breast Cancer Res 2004;6(1):R8-R17. 
70. Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according 
to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 
2007;43(10):1548-55. 
71. Gribbin J, Dewis R. Adjuvant! Online: review of evidence concerning its validity, and 
other considerations relating to its use in the NHS. NICE Clinical Guidelines, No. 80: Early 
and Locally Advanced Breast Cancer: Diagnosis and Treatment 2009, 
28 
 
http://www.ncbi.nlm.nih.gov/books/NBK11639/:Appendix 1. 
http://www.ncbi.nlm.nih.gov/books/NBK11639/. 
72. Department of Health PbR Team. NHS 2010-11 reference costs publication. In: 
Department of Health; 2011. 
73. Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and 
BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer 
Res Treat 2011;129(1):185-90. 
74. Tung N, Garber JE, Lincoln A, et al. Frequency of triple-negative breast cancer in 
BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other 
mutations. J Clin Oncol 2012;30(35):4447-8. 
75. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of 
BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18(4):287-95. 
76. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis 
and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10(2):169-80. 
77. Lipton A, Hershey S. Bone Metastases in Breast Cancer. Business Briefing: US 
Oncology Review, 2006, 
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&cad=rja&
uact=8&ved=0CCwQFjAA&url=http%3A%2F%2Fwww.touchoncology.com%2Fsystem%2
Ffiles%2Fprivate%2Farticles%2F1272%2Fpdf%2Fonco849.pdf&ei=qk-
LU_WNKcKxO5qSgJgP&usg=AFQjCNH9r5UlNguPh5Kf76qoKytyttBwLw&bvm=bv.6772
0277,d.ZGU. 
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&cad=rja&
uact=8&ved=0CCwQFjAA&url=http%3A%2F%2Fwww.touchoncology.com%2Fsystem%2
Ffiles%2Fprivate%2Farticles%2F1272%2Fpdf%2Fonco849.pdf&ei=qk-
LU_WNKcKxO5qSgJgP&usg=AFQjCNH9r5UlNguPh5Kf76qoKytyttBwLw&bvm=bv.6772
0277,d.ZGU. 
78. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor 
recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel 
Project node-positive adjuvant breast cancer trials. J Clin Oncol 2006;24(13):2028-37. 
79. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor 
recurrence and locoregional recurrences in patients treated by breast-conserving therapy in 
five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast 
cancer. J Clin Oncol 2009;27(15):2466-73. 
29 
 
80. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients 
over a 20-year period: a retrospective analysis based on individual patient data from six 
consecutive studies. Cancer 2005;104(8):1742-50. 
81. Office of National Statistics. Lifetable for females in the UK. 
http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Interim+Life+Tables. 
82. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation 
carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 
2013;105(11):812-22. 
83. CRUK. Ovarian Cancer Incidence Statistics: 2011. 2014, 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-
cancer-incidence-statistics#age:accessed from http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics#age , access 
date 10/03/2015. http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics#age. 
84. SEER. Cancer Stat Facts: Ovary Cancer. 
2014:http://seer.cancer.gov/statfacts/html/ovary.html  (accessed 10/01/2017). 
85. SEER. Cancer Stat Facts: Female Breast Cancer. 2014, 
https://seer.cancer.gov/statfacts/html/breast.html:https://seer.cancer.gov/statfacts/html/breast.
html (date accessed: 20.01.2017). https://seer.cancer.gov/statfacts/html/breast.html. 
86. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a 
summary of evidence. Breast Cancer Res Treat 2010;119(1):13-24. 
87. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast 
cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357(2):115-23. 
88. CRUK. Breast Cancer Survival Statistics. One-, five-, and ten-year survival, 2011, 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/survival/breast-cancer-
survival-statistics:http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/survival/breast-cancer-survival-statistics. 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/survival/breast-cancer-
survival-statistics. 
89. Kotsopoulos J, Rosen B, Fan I, et al. Ten-year survival after epithelial ovarian cancer 
is not associated with BRCA mutation status. Gynecol Oncol 2016;140(1):42-7. 
90. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and 
BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Jama 
2012;307(4):382-90. 
30 
 
91. CRUK. Ovarian Cancer Survival Statistics 2010-2011. 2014, 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/survival/ovarian-
cancer-survival-statistics:accessed from http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/survival/ovarian-cancer-survival-statistics  (access date 
11/03/2015). http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/survival/ovarian-cancer-survival-statistics. 
92. Grann VR, Patel P, Bharthuar A, et al. Breast cancer-related preferences among 
women with and without BRCA mutations. Breast Cancer Res Treat 2010;119(1):177-84. 
93. Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-
related utilities for health states relevant to ovarian cancer diagnosis and treatment. 
Gynecologic oncology 2009;113(2):216-20. 
94. Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation 
of health care programmes. Third Edition ed. Oxford Oxford University Press; 2005. 
95. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a 
chronic disease. The oncologist 2002;7 Suppl 5:20-8. 
96. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at 
diagnosis, and mortality. Cancer 1993;71(2 Suppl):517-23. 
97. Swart A. Long-term follow-up of women enrolled in a randomized trial of adjuvant 
chemotherapy for early stage ovarian cancer. In: ASCO Annual Meeting Proceedings (Part I), 
2007: Abstract 25, p. 18S (June 20 Supplement): 5509. Journal Clinical Oncology. 
98. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert 
review of pharmacoeconomics & outcomes research 2010;10(5):553-66. 
 
